Ling Min Gao, MD
Internal Medicine · Flushing, NYNPI 1215947429
Payments from drug & device makers
Across 719 payments — averaging $34.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- AbbVie$4K
- Gilead$3K
- GSK$2K
- Johnson & Johnson$2K
- Boehringer Ingelheim$1K
- plus $10K from 31 others
What the payments were for
- Food & beverage$24,924100%
- Education$380%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 113 | $3,657 |
| AbbVie(2 entities) | 77 | $3,513 |
| Gilead | 77 | $2,737 |
| GSK | 64 | $2,206 |
| Johnson & Johnson | 23 | $1,579 |
| Boehringer Ingelheim | 40 | $1,238 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $1,126 |
| Amarin Pharma, Inc. | 35 | $845 |
| Novo Nordisk | 26 | $815 |
| Bayer | 35 | $731 |
| Ironwood Pharmaceuticals, Inc | 32 | $724 |
| Merck | 20 | $700 |
| Amgen | 10 | $617 |
| Phathom Pharmaceuticals, Inc. | 6 | $602 |
| Sanofi-aventis U.S. LLC | 18 | $547 |
| Axsome Therapeutics, Inc. | 4 | $513 |
| Kowa Pharmaceuticals America, Inc. | 30 | $447 |
| Lilly USA, LLC | 19 | $416 |
| Nestle Healthcare Nutrition Inc. | 10 | $394 |
| Novartis | 7 | $236 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $207 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $206 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Neurocrine Biosciences, Inc. | 1 | $124 |
| Arbor Pharmaceuticals, Inc. | 8 | $122 |
| Ardelyx, Inc. | 5 | $116 |
| Insmed, Inc. | 3 | $73 |
| Sanofi Pasteur Inc. | 3 | $53 |
| Pfizer | 2 | $47 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Genentech USA, Inc. | 2 | $40 |
| Exact Sciences | 2 | $39 |
| Biogen | 2 | $36 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Calliditas Therapeutics US Inc. | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,962 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 153 | $138,035 |
| VascepaIcosapent Ethyl | 262 | $133,864 |
| FarxigaDapagliflozin Propanediol | 144 | $118,919 |
| VemlidyTenofovir Alafenamide | 49 | $70,864 |
| JanuviaSitagliptin Phosphate | 88 | $70,148 |
| LinzessLinaclotide | 86 | $68,504 |
| RybelsusSemaglutide | 37 | $55,965 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $39,684 |
| LivaloPitavastatin Calcium | 54 | $38,677 |
| KerendiaFinerenone | 27 | $37,904 |
| Lactulose | 15 | $32,428 |
| ProliaDenosumab | 19 | $32,424 |
| XareltoRivaroxaban | 36 | $31,576 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 22 | $31,058 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $30,373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $1,238 | $166,552191 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $3,657 | $153,468191 claims |
| MerckJanuvia, Janumet Xr | $700 | $88,793129 claims |
| Novo NordiskRybelsus, Ozempic | $815 | $83,35952 claims |
| AbbVieLinzess, Synthroid | $3,513 | $72,242136 claims |
| GileadVemlidy | $2,737 | $70,86449 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Shingrix | $2,206 | $50,21289 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $447 | $38,67754 claims |
| BayerKerendia | $731 | $37,90427 claims |
| AmgenProlia | $617 | $32,42419 claims |
| Johnson & JohnsonXarelto | $1,579 | $31,57636 claims |
| PfizerEliquis | $47 | $23,40316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Flushing
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.